North America Endometriosis Market Size, Share & Industry Trends Analysis Report By Type, By Treatment (Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others), By Distribution Channel, By Country and Growth Forecast, 2022 - 202

North America Endometriosis Market Size, Share & Industry Trends Analysis Report By Type, By Treatment (Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others), By Distribution Channel, By Country and Growth Forecast, 2022 - 2028

The North America Endometriosis Market would witness market growth of 11.0% CAGR during the forecast period (2022-2028).

Endometriosis does not have a known aetiology. There have been various hypotheses put forth. The disorder typically runs in families. Additionally, it has a greater impact on some ethnic groups than others. The fallopian tubes allow some of the uterine lining to rise. Instead of exiting the body as a period, it embeds itself in the pelvic organs. The body's built-in defence against disease and infection has a problem.

Endometrium cells migrate across the body through the lymphatic or blood systems. The immune system is made up of a number of tubes and glands. These hypotheses do not fully elucidate the causes of endometriosis. The illness is probably brought on by a number of different factors working together.

Women frequently experience the health issue of endometriosis. More than 6.5 million women in the US, or at least 11% of all women, are thought to have endometriosis. Endometriosis develops when tissue that resembles the uterine lining (womb lining) grows outside of the uterus. More than 11% of American women between the ages of 15 and 44 may be affected. It may make it more difficult to become pregnant and is particularly prevalent in women in their 30s and 40s. The symptoms can be controlled with a variety of treatments, which can also increase the chances of getting pregnant. The high endometriosis prevalence in North America is anticipated to increase the demand for endometriosis therapy.

The US market dominated the North America Endometriosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $615.8 million by 2028. The Canada market is poised to grow at a CAGR of 13.5% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 12.5% during (2022 - 2028).

Based on Type, the market is segmented into Superficial Peritoneal Lesion, Endometriomas, and Others. Based on Treatment, the market is segmented into Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.

Scope of the Study

Market Segments covered in the Report:

By Type

• Superficial Peritoneal Lesion
• Endometriomas
• Others

By Treatment

• Oral Contraceptives
• Gonadotropin-releasing hormone (GnRH) medicines
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Teva Pharmaceuticals Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Sanofi S.A.
• AbbVie, Inc.
• AstraZeneca PLC
• Pfizer, Inc.
• Merck & Co., Inc.
• GlaxoSmithKline PLC
• Abbott Laboratories
• Consilient Health Limited

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free